Answers are grounded in this paper and cite their sources.
Introduction Viral load (VL) testing is recommended for monitoring antiretroviral therapy (ART), whereas CD4 testing is increasingly targeted. Changes in these practices across Asia-Pacific remain unclear. We examined trends in VL and CD4 testing rates and their associations with AIDS diagnosis and mortality. Methods We analysed multicentre cohort data from adults receiving ART during 2003–2018 using Poisson and Fine-Gray competing-risk regression. Results Among 8,446 patients, VL testing rates remained steady at one test per person-year during 2003−2018. Increased VL testing was associated with more frequent CD4 testing (>2 tests in the previous year; incidence rate ratio (IRR)=1.57, 95%CI 1.53–1.60), later follow-up years (2008−2012: IRR = 1.15, 95%CI 1.12–1.18; 2013−2015: IRR = 1.07, 95%CI 1.04–1.10), older age (31−40years: IRR = 1.06, 95%CI 1.03–1.08; 41−50years: IRR = 1.08, 95%CI 1.05–1.11; > 50years: IRR = 1.07, 95%CI 1.03–1.11), higher current VL (401−1000 copies/mL: IRR = 1.16, 95%CI 1.09–1.24; > 1000 copies/mL: IRR = 1.07, 95%CI 1.04–1.11), initial ART regimen (nucleoside/nucleotide reverse transcriptase inhibitor plus protease inhibitor (NRTI+PI): IRR = 1.07, 95%CI 1.04–1.10; other combinations: IRR = 1.11, 95%CI 1.05–1.17), and higher country income levels (upper-middle: IRR = 2.17, 95%CI 2.11–2.23; high: IRR = 3.14, 95%CI 3.03–3.26). CD4 testing rates decreased from 2.04 to 1.06 tests per person-year over the same period. Lower CD4 testing rate was associated with HIV exposure mode (men who have sex with men (MSM): IRR = 0.94, 95%CI 0.92–0.96; injecting drug use (IDU): IRR = 0.93, 95%CI 0.90–0.97; other/unknown: IRR = 0.90, 95%CI 0.87–0.93), higher current CD4 (201−350 cells/µL: IRR = 0.95, 95%CI 0.93–0.97; 351−500 cells/µL: IRR = 0.89, 95%CI 0.87–0.91; > 500 cells/µL: IRR = 0.85, 95%CI 0.83–0.87) and receiving an NRTI+PI first-line combination (IRR = 0.96, 95% CI 0.94–0.98). VL and CD4 testing rates were not significantly associated with AIDS diagnosis. However, having >2 CD4 tests in the previous year was associated with higher mortality risk. Conclusion VL testing was broadly consistent with annual monitoring, although individual gaps may remain. Differentiated strategies should maintain annual VL testing and targeted CD4 testing for advanced HIV disease.
No takes yet. Share an insight, caveat, or question.
Pasayan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: